Mode
Text Size
Log in / Sign up
Phase 4 N=70 Randomized Single-blind Treatment

Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus

Type 1 Diabetes · Pregnancy, High Risk

Enrolled (actual)
70
Serious AEs
0.0%
Results posted
Jul 2024
Primary outcome: Primary: Neonatal Hypoglycemia — 49.2; 50.1 mg/dL

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Insulin (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Gianna Wilkie
Primary completion
May 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Neonatal Hypoglycemia
49.2; 50.1
SECONDARY
Number of Maternal Hypoglycemic Events
5; 1
SECONDARY
Development of Diabetic Ketoacidosis During Labor
0; 0
SECONDARY
Mode of Delivery
17; 23; 16; 11; 2; 1
SECONDARY
Neonatal Birthweight
3067.8; 3293.3
SECONDARY
Number of Participants With Shoulder Dystocia
4; 1
SECONDARY
Number of Participants With Brachial Plexus Injury
0; 0
SECONDARY
5 Minute Apgar Score < 7
7; 3
SECONDARY
Received Neonatal Intervention for Hypoglycemia
18; 20
SECONDARY
Neonatal Intensive Care Unit Admission
16; 17
SECONDARY
Gestational Age at Delivery
35.6; 36.0
SECONDARY
Number of Participants With Neonatal Respiratory Distress
4; 2
SECONDARY
Number of Participants With Neonatal Hyperbilirubinemia
3; 3

Summary

The purpose of this study is to perform a randomized trial to investigate if intrapartum insulin delivery mechanisms reduces adverse outcomes associated with type 1 diabetes in pregnancy. The investigators aim to compare subcutaneous insulin pump versus intravenous insulin infusion with regard to the primary outcome of neonatal blood sugar.

Eligibility Criteria

Inclusion Criteria

  • Pregnant women with pre-gestational diagnosis of type 1 diabetes mellitus and managed on an insulin pump in pregnancy
  • Pregnancy and delivery care obtained at University of Massachusetts (UMass) Memorial Medical Center
  • Patients able to provide written informed consent

Exclusion Criteria

  • Patients who are under the age of 18
  • Patients with altered state of consciousness
  • Critically ill patient requiring intensive care unit admission
  • Patient at risk for suicide
  • Patient refuses or is otherwise unable to participate in own care
  • Patient without pump supplies
  • Patients presenting with diabetic ketoacidosis on admission
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04599075). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search